Bumpy ride for BTG and Astra after trials failure
Thursday 09 August 2012
Related articles
AstraZeneca and BTG yesterday axed plans to develop a new drug to treat severe blood poisoning after it failed medical trials.
Stage II trials comparing doses of the duo's CytoFab treatment with placebo drugs in patients with severe septicaemia or septic shock "did not show any significant improvements versus the placebo", the firms admitted.
As a result, the drug has been shelved, leaving BTG, led by Louise Makin, with a £28m charge for this financial year. Its shares were knocked back in early trading, although by the end of the day the stock had recovered. AstraZeneca shares lost 61p to 3015p but most of that was because its dividend was being paid out yesterday.
-
Anonymity order lifted for triple child killer David McGreavy jailed in 1973
-
World news in pictures
-
Far-right French historian, 78-year-old Dominique Venner, commits suicide in Notre Dame in protest against gay marriage
-
Plenty of Fish dating site founder pulls 'Intimate Encounters' option to ward off sleazy men
-
Video emerges of Pope Francis reportedly performing an exorcism in St Peter’s Square
- 1 Gay couple beaten in park urge MPs to moderate language on gay marriage
- 2 After woman sells virginity for $780,000, here are the results of our prostitution survey
- 3 China agrees to impose carbon targets by 2016
- 4 Exclusive: Championship clubs set to push for safe-standing trials
- 5 Far-right French historian, 78-year-old Dominique Venner, commits suicide in Notre Dame in protest against gay marriage
Get your summer started with British Military Fitness
BMF is the UK’s biggest and best loved outdoor fitness classes
Visit York
Find out what The Independent's resident travel expert has to say about one of the most beautiful small cities in the world
Enter the latest Independent competitions
Win anything from gadgets to five-star holidays on our competitions and offers page.
Business videos from commercial thought leaders
Watch the best in the business world give their insights into the world of business.
Day In a Page
How to say ‘I’m a sellout’
Why clubs are keen to take a stand


Comments